No Data
H.C. Wainwright Maintains Immix Biopharma(IMMX.US) With Buy Rating, Maintains Target Price $7
H.C. Wainwright analyst Robert Burns maintains $Immix Biopharma(IMMX.US)$ with a buy rating, and maintains the target price at $7.According to TipRanks data, the analyst has a success rate of 24.2%
Buy Rating Affirmed for Immix Biopharma Amid Promising NXC-201 Trial Outcomes and Market Potential
Express News | Immix Biopharma Inc - Data From Ex-US Clinical Trial Reported at Asgct 2024 Showed a 92% Overall Response Rate
Express News | Immix Biopharma Doses 1St Patient in U.S. Al Amyloidosis Trial With CAR-T Nxc-201
Immix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial With CAR-T NXC-201
Data from ex-US clinical trial reported at ASGCT 2024 showed a 92% overall response rate
H.C. Wainwright Initiates Immix Biopharma(IMMX.US) With Buy Rating, Announces Target Price $7
H.C. Wainwright analyst Robert Burns initiates coverage on $Immix Biopharma(IMMX.US)$ with a buy rating, and sets the target price at $7.According to TipRanks data, the analyst has a success rate of 2